| 引用本文: | 范晓梅,李文周,张竞佳,林微,许晨舒,周艳莹,钟智,吴立明,陈瑜,钟明,申新田,郭惠娟.PDCA循环管理干预儿科辅助用药磷酸肌酸钠的临床效果评价[J].中国现代应用药学,2019,36(5):580-583. |
| FAN Xiaomei,LI Wenzhou,ZHANG Jingjia,LIN Wei,XU Chenshu,ZHOU Yanying,ZHONG Zhi,WU Liming,CHEN Yu,ZHONG Ming,SHEN Xintian,GUO Huijuan.Evaluation of PDCA Cycle to Intervene the Clinical Use of Adjuvant Drug Creatine Phosphate Sodium in Pediatric Department[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(5):580-583. |
|
| |
|
|
| 本文已被：浏览 1992次 下载 1080次 |
码上扫一扫！ |
|
|
| PDCA循环管理干预儿科辅助用药磷酸肌酸钠的临床效果评价 |
|
范晓梅1, 李文周1,2, 张竞佳1, 林微3, 许晨舒3, 周艳莹4, 钟智4, 吴立明1, 陈瑜1, 钟明1, 申新田1, 郭惠娟1
|
|
1.暨南大学附属深圳市宝安区妇幼保健院, 广东 深圳 518101;2.深圳市龙岗区耳鼻咽喉医院, 广东 深圳 518172;3.深圳大学医学部药学院, 广东 深圳 518060;4.中山大学药学院, 广州 510006
|
|
| 摘要: |
| 目的 探讨PDCA循环管理规范儿科辅助用药磷酸肌酸钠的临床使用，促进辅助用药的合理应用。方法 采用回顾性分析方法，通过医院信息系统选取儿科使用磷酸肌酸钠的病历1 300份，其中2015年1月-2016年7月期间700份为PDCA循环干预前组，2016年9月-2017年2月期间300例病历为第1轮干预组，2017年3月-9月期间300例病历为第2轮干预组，对比分析持续干预前后磷酸肌酸钠的用药情况。结果 实施2轮PDCA循环管理干预后，儿科磷酸肌酸钠使用显著减少，用药频度由736（干预前）降至193（干预后），且用药合理率明显提高，从干预前66.86%提高至第2轮干预后的93.00%。结论 PDCA循环管理法在规范儿科辅助用药磷酸肌酸钠的临床合理使用中持续改进的效果显著。 |
| 关键词: PDCA 磷酸肌酸钠 儿科 合理用药 持续改进 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.05.014 |
| 分类号:R969.4 |
| 基金项目:国家自然科学基金项目（81603185）；深圳市科技计划项目（JCYJ20160429171911146）；深圳市卫生计生系统科研项目（201605024）；深圳市宝安区医疗卫生科研项目（2018JD266）；深圳市龙岗区医疗卫生科技计划项目（20160608104609244） |
|
| Evaluation of PDCA Cycle to Intervene the Clinical Use of Adjuvant Drug Creatine Phosphate Sodium in Pediatric Department |
|
FAN Xiaomei1, LI Wenzhou1,2, ZHANG Jingjia1, LIN Wei3, XU Chenshu3, ZHOU Yanying4, ZHONG Zhi4, WU Liming1, CHEN Yu1, ZHONG Ming1, SHEN Xintian1, GUO Huijuan1
|
|
1.Shenzhen Bao'an Maternity and Child Health Hospital, Jinan University, Shenzhen 518101, China;2.Longgang ENT Hospital, Shenzhen 518172, China;3.Health Science Center of Pharmacy, Shenzhen University, Shenzhen 518060, China;4.School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
|
| Abstract: |
| OBJECTIVE The application of PDCA cycle in rationalizing the clinical use of creatine phosphate sodium in pediatric department was explored to promote the rational use of adjuvant drug in the clinic. METHODS In retrospective analysis, 1 300 medical records of pediatric department involving creatine phosphate sodium were selected with HIS (Hospital information system), including 700 medical records from January, 2015 to July, 2016 before PDCA cycle management, 300 records from September, 2016 to February, 2017 after the first PDCA cycle management and 300 records from March to September, 2017 after the second PDCA cycle management. The use of creatine phosphate sodium was analyzed comparatively before and after PDCA cycle intervention. RESULTS After 2 cycles of PDCA cycle management intervention, the monthly DDDs value of creatine phosphate sodium in pediatric department was significantly decreased from 763 before PDCA cycle intervention to 193 after two PDCA cycles, and the rational rate of creatine phosphate sodium was significantly improved from 66.86% before intervention to 93.00% after two PDCA cycles. CONCLUSIONS PDCA cycle management could significantly promote continuous improvement for the clinical use of creatine phosphate sodium in pediatric department. |
| Key words: PDCA creatine phosphate sodium pediatric department rational drug use continuous improvement |
|
|
|
|
